EGI
BPMC

EAM Global Investors’s Blueprint Medicines BPMC Stock Holding History

EAM Global Investors’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-41,242
Closed -$4.45M – 105
2024
Q2 		$4.45M Buy
41,242
+1
+0% +$100 1% 61
2024
Q1 		$3.91M Hold
41,241
– – 0.9% 72
2023
Q4 		$3.8M Buy
+41,241
New +$2.67M 0.92% 59

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EAM Global Investors's BPMC Position: Q3 2024 in Review

EAM Global Investors sold out of Blueprint Medicines (BPMC) in Q3 2024, closing a stake of 41,242 shares — an estimated $4.45M sold.

EAM Global Investors first reported a position in BPMC in Q4 2023 and held it in 3 quarters. The position peaked at $4.45M in Q2 2024. 319 funds tracked by Wall St. Rank hold BPMC as of Q3 2024.

  • EAM Global Investors reported no remaining Blueprint Medicines position as of Q3 2024 after selling out during the quarter.
  • EAM Global Investors sold 41,242 Blueprint Medicines shares in Q3 2024, an estimated $4.45M.
  • EAM Global Investors first reported a position in Blueprint Medicines in Q4 2023 and held it in 3 quarters.
  • EAM Global Investors's Blueprint Medicines position peaked at $4.45M in Q2 2024.
  • 319 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2024.

Based on EAM Global Investors's 13F filing for Q3 2024, filed 13 Nov 2024.